Influenza Clinical Trial
Official title:
A Phase I Study of the Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle
Title: A Phase I Study of The Safety, Reactogenicity, Acceptability and Immunogenicity of
Inactivated Influenza Vaccine Delivered either by Microneedle Patch or by Hypodermic Needle.
This is a single center, partially blinded, randomized phase I study in which healthy adult
subjects (ages 18-49) will receive either inactivated influenza vaccine (IIV) (either by
microneedle patch or hypodermic needle) or placebo (by microneedle patch). This study is
designed to investigate the safety, reactogenicity, acceptability and immunogenicity of an
inactivated influenza vaccine delivered by microneedle patch.
Title: A Phase I Study of The Safety, Reactogenicity, Acceptability and Immunogenicity of
Inactivated Influenza Vaccine Delivered either by Microneedle Patch or by Hypodermic Needle.
Population: healthy adults, 18-49 years inclusive
Number of Sites: One
Study Duration: 12 months
Subject Duration: 6 months
Objectives:
Primary:
To evaluate the safety and reactogenicity following receipt of inactivated influenza vaccine
delivered by microneedle patch (either by staff or self-administered).
Secondary:
To evaluate the HAI titers following receipt of inactivated influenza vaccine delivered
either by microneedle patch or by hypodermic needle (both vaccines administered by study
staff).
To evaluate unsolicited adverse events following receipt of IIV delivered by microneedle
patch (administered by study staff or self-administered).
To evaluate new-onset chronic illnesses (NOCI) following receipt of IIV delivered by
microneedle patch (administered by study staff or self-administered).
Exploratory:
To evaluate microneutralizing antibody titers following receipt of inactivated influenza
vaccine delivered either by microneedle patch or by hypodermic needle (both vaccines
administered by study staff).
To evaluate HAI +/- microneutralization and ELISA titers following receipt of inactivated
influenza vaccine delivered by microneedle patch (administered by study staff or self-
administered) and compare to inactivated influenza vaccine delivered by hypodermic needle
(administered by study staff).
To evaluate HAI +/- microneutralization and ELISA titers following receipt of inactivated
influenza vaccine delivered by microneedle patch (administered by study staff) and compare to
inactivated Influenza vaccine delivered by microneedle patch (self-administered).
To evaluate T follicular helper cells following receipt of inactivated influenza vaccine
delivered by microneedle patch (administered by study staff or self-administered) and compare
to inactivated influenza vaccine delivered by hypodermic needle (administered by study
staff).
To evaluate innate immunity signatures by microarrays following receipt of inactivated
influenza vaccine delivered by microneedle patch (administered by study staff or
self-administered) and compare to inactivated influenza vaccine delivered by hypodermic
needle (administered by study staff).
To evaluate B memory cells, CD4 and CD8 central memory and effector T cells, intracellular
cytokine staining (ICS) for interferon-gamma and interleukin-4, cross reactive T cells
following receipt of inactivated influenza vaccine delivered by microneedle patch
(administered by study staff or self- administered) and compare to inactivated influenza
vaccine delivered by hypodermic needle (administered by study staff).
To evaluate the acceptability of inactivated Influenza vaccine delivered by microneedle patch
(administered by study staff or self-administered) and compare to inactivated influenza
vaccine delivered by hypodermic needle (administered by study staff).
Schematic of Study Design:
This is a single center, partially blinded, randomized phase I study in which healthy adult
subjects (ages 18-49) will receive either inactivated influenza vaccine (IIV) (either by
microneedle patch or hypodermic needle) or placebo (by microneedle patch). This study is
designed to investigate the safety, reactogenicity, acceptability and immunogenicity of an
inactivated influenza vaccine delivered by microneedle patch.
A total of 100 subjects (25 subjects in each group) will be randomized to one of four groups
as in the schematic of the study design below.
Group A: Inactivated influenza vaccine delivered by microneedle patch administered by study
staff Group B: Inactivated influenza vaccine delivered by intramuscular injection
administered by study staff Group C: Inactivated influenza vaccine delivered by microneedle
patch administered by subject Group D: Placebo delivered by microneedle patch and
administered by study staff
Each subject will have 6 clinic visits: D0, D2 (+1 day), D8 (+2 days), D28 (+/- 2 days), D56
(+/- 5 days), and D180( +/- 14 days).
Blood draws will be obtained at 6 clinic visits to evaluate for immunogenicity (D0, D2 (+1
day) D8 (+ 2 days) - D28 (+/- 2 days), D56 (+/- 5 days), and D180 (+/- 14 days)) and at four
clinic visits for safety (D0, D2 (+1 day), D8 (+2 days), and D28 (+/- 2 days)).
Safety will be measured by the occurrence of solicited injection site and systemic
reactogenicity on the day of study product administration through 7 days after, and serious
adverse events (SAEs) and new-onset chronic medical conditions through 180 days after study
product administration.
Immunogenicity testing will include performing hemagglutination inhibition (HAI) +/-
microneutralizing antibody assays as well as other adaptive immune assays on D0 prior to
study product administration and at D8 (+2 days) , D28 (+/- 2 days), D56 (+/-5 days), and
D180 (+/-14 days)) .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
| Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
| Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
| Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
| Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
| Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
| Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
| Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
| Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
| Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
| Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
| Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
| Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |